Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis

Molecular characterization of Philadelphia chromosome-negative (Ph−) chronic myeloproliferative disorders, such as systemic mastocytosis (SM), has provided a clear rationale for investigating novel targeted therapies. The tyrosine kinase (TK) inhibitor dasatinib is 325-fold more potent against Bcr-A...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Clin Cancer Res
Huvudupphovsmän: Verstovsek, Srdan, Tefferi, Ayalew, Cortes, Jorge, O’Brien, Susan, Garcia-Manero, Guillermo, Pardanani, Animesh, Akin, Cem, Faderl, Stefan, Manshouri, Taghi, Thomas, Deborah, Kantarjian, Hagop
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2008
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5018899/
https://ncbi.nlm.nih.gov/pubmed/18559612
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-0366
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk